Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(62)

カスタマーフィードバック(10)

Quality Control & MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 NHvS[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfBbZk4OiCq NVXkVm5ZTE2VTx?= MYXJR|UxRTBwMECwNFch|ryP Mk\kNVc6PTZyOEC=
K562 NI\uco9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHGO|IhcA>? NV[4U4VFTE2VTx?= MoDoTWM2OD1yLkCwNUDPxE1? NYfk[ZFKOTd7NU[wPFA>
M07e MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P5eFczKGh? MnXzSG1UVw>? M1;MemlEPTB;MD6wNFEzKM7:TR?= NXPqeFc{OTd7NU[wPFA>
ALL3 NYi1SIJTS3m2b4TvfIlkKEG|c3H5 NWfOT3BOOC5zzszN NYG2d2N[PzJiaB?= MUfEUXNQ MkHHTWM2OD1yLkCwNFQh|ryP MVuxPVg5QTV2MB?=
CML MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\jNlAhdWmw NX76NHVyTE2VTx?= NVnHNlQ4UUN3ME2wMlAxOSEQvF2= NH7aNZcyQTJzOUCxOi=>
BA/F3 NFLrO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYP2NWRvPzJiaB?= MW\EUXNQ NVjNbW5NUUN3ME22MlU5QSEQvF2= MlL5NlMxQDh4NES=
BA/F3 NIjhUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqwTopZPzJiaB?= MUPEUXNQ M2raPGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN MmfqNlMxQDh4NES=
BA/F3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfHUmViPzJiaB?= NUHn[3lETE2VTx?= MmWwTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>? MUOyN|A5QDZ2NB?=
BA/F3 NWm1fmh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n1VlczKGh? NWe4d3pxTE2VTx?= MojxTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MWmyN|A5QDZ2NB?=
BA/F3 NHOzVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f3T|czKGh? NIjSUJFFVVOR MVzJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? Ml3qNlM{ODF5MEO=
BA/F3 NYDhbnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp MWjEUXNQ NIPPU3hKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= M3LqbVI{OzBzN{Cz
BA/F3 M3S5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ezeVczKGh? NIm4e4VFVVOR Mm\sTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? M4LTd|I{OzBzN{Cz
BA/F3 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTTcWhbPzJiaB?= MXnEUXNQ NYfrSo1wUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MVqyN|MxOTdyMx?=
BA/F3 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fwZVczKGh? Ml3WSG1UVw>? MULJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? NUnNdWY5OjN|MEG3NFM>
BA/F3 MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr1O|IhcA>? MlvYSG1UVw>? MWrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> NGnCZ|UzOzNyMUewNy=>
BA/F3 NWq5VWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp MWXEUXNQ NXjF[m5JUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiWUK1N2ghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOjQQvF2= NFTPVpUzOzNyMUewNy=>
BA/F3 NEjMNVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;2UFczKGh? M1TNRWROW09? NGL4bphKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? M3zDVVI{OzBzN{Cz
BA/F3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3NkBp Ml\DSG1UVw>? M{K5OWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?= NEm5Z4IzOzNyMUewNy=>
T cell MlO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjVdlU4OiCq NHi1UmhFVVOR MXTJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> MYmxO|E2PDVzMh?=
WiDr NHLaPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXzO|IhcA>? MkPiSG1UVw>? NH\2bWpKSzVyPUCuNFUzKM7:TR?= MYCxOVYyPTVzMh?=
PC3 Mn;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGz[nVHPzJiaB?= MV;EUXNQ MnnvTWM2OD1yLkCwPVQh|ryP M4GydlE2PjF3NUGy
MDA-MB-231 NVP3VZpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvFV4psPzJiaB?= M4e4cmROW09? NI\XeJJKSzVyPUCuNFEzKM7:TR?= MUOxOVYyPTVzMh?=
Hs578T MWDDfZRwfG:6aXOgRZN{[Xl? NXfEbZIxPzJiaB?= NWPUXXNwTE2VTx?= MXfHTVUxRTBwMEOg{txO Mo\YNlQxOTV|Mke=
HMEC MniwR5l1d3SxeHnjJGF{e2G7 M4T3[VczKGh? M1SySmROW09? M1vLRWdKPTB;MT64JO69VQ>? NGj1OIgzPDBzNUOyOy=>
DU145 MWDDfZRwfG:6aXOgRZN{[Xl? MYO3NkBp NXjVT5I2TE2VTx?= NVvYVZBsT0l3ME2wMlE3KM7:TR?= M4r5d|I1ODF3M{K3
U251 MWrDfZRwfG:6aXOgRZN{[Xl? MX:3NkBp M4nVfmROW09? NXjNXos5T0l3ME2yMlgyKM7:TR?= M1;pflI1ODF3M{K3
NCI60 NV7GXYFLS3m2b4TvfIlkKEG|c3H5 Ml\tO|IhcA>? M1voOmROW09? MWDHTVUxRTVwNzFOwG0> MUKyOFAyPTN{Nx?=
MALME-3M M2WySWN6fG:2b4jpZ{BCe3OjeR?= MX23NkBp M3nFWmROW09? MYjHTVUxRTZwNkGg{txO NFHL[WkzPDBzNUOyOy=>
KM12 M{TPS2N6fG:2b4jpZ{BCe3OjeR?= NFOzV2s4OiCq M3fRSGROW09? M3j5W2dKPTB;Nz60OEDPxE1? MUCyOFAyPTN{Nx?=
SW620 NXvwfYtyS3m2b4TvfIlkKEG|c3H5 NUj5fnF7PzJiaB?= MmO0SG1UVw>? MmnHS2k2OD16LkSzJO69VQ>? NYXpR3I1OjRyMUWzNlc>
RXF 393NL NFW1TXFEgXSxdH;4bYMhSXO|YYm= M{HDR|Qh\GG7cx?= NHXmNmpFVVOR NHz1O|FKSzVyPUCuNFIyPyEQvF2= MoX5NlMzPTNyN{S=
LXFA 983L MmjkR5l1d3SxeHnjJGF{e2G7 MWC0JIRigXN? NV20Zmd3TE2VTx?= MU\JR|UxRTBwMEW2OUDPxE1? MkDZNlMzPTNyN{S=
PRXF DU145 M2Trd2N6fG:2b4jpZ{BCe3OjeR?= Mm\2OEBl[Xm| M1jUOmROW09? NX;Udms4UUN3ME2wMlA3OjNizszN MUOyN|I2OzB5NB?=
PAXF 1657L NEXqTmNEgXSxdH;4bYMhSXO|YYm= NIXFS4g1KGSjeYO= NVrBUnRnTE2VTx?= MlLGTWM2OD1yLkGyNUDPxE1? MVKyN|I2OzB5NB?=
CXF 1103L MoG1R5l1d3SxeHnjJGF{e2G7 NXLlZWxpPCCmYYnz NWrs[3JvTE2VTx?= M4rPdWlEPTB;ND6zOkDPxE1? M4HNXlI{OjV|MEe0
GXF251L MlG1R5l1d3SxeHnjJGF{e2G7 MYq0JIRigXN? MkS2SG1UVw>? M{Sw[2lEPTB;Mj6yOUDPxE1? MUSyN|I2OzB5NB?=
NCI-H23 M1XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTmO|IhcA>? MnmzSG1UVw>? NH\SeYZKSzVyPUKuNlch|ryP MVeyN|UzOTB{MB?=
HCT116 M1;HWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrmNFE4OiCq MkLWSG1UVw>? NVG0VXRvUUN3ME2yMlMh|ryP MWmyN|UzOTB{MB?=
MCF7 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf6cmZkPzJiaB?= MX7EUXNQ NILPbItKSzVyPUKuOVch|ryP MWWyN|UzOTB{MB?=
NCI-H460 MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHLNpo4OiCq MYrEUXNQ M3XINWlEPTB;OD65PUDPxE1? NELBSHYzOzV{MUCyNC=>
DLD1 NV7qT5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWS3NkBp NV72b2cyTE2VTx?= NGDZUGVKSzVyPUSuOkDPxE1? NHHGbZozOzV4N{m2NC=>
NCI-H661 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO1O4M4OiCq M3y3TGROW09? NHHr[2hKSzVyPUeuPEDPxE1? MXWyN|U3Pzl4MB?=
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3NkBp NXLsbpIzTE2VTx?= MUXJR|UxRThwMjFOwG0> MYCyN|U3Pzl4MB?=
U937 M3;P[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTHS3c4OiCq MVPEUXNQ M1Ts[GlEPTB;MUKuNkDPxE1? Ml3VNlM2Pjd7NkC=
HEK293 Mke1SpVv[3Srb36gRZN{[Xl? MW[xNOKh|ryP NIfkZ41FVVOR NWPCS5B5UW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> Mn\DNlI4PzB4MUC=
HUVEC Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:wMlE2yqEQvF2= MlPpO|IhcA>? MXnEUXNQ M1;ZZmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> MWqyNlg2Ozl7Mx?=
HUVEC MW\GeY5kfGmxbjDBd5NigQ>? Mn3tNVXDqM7:TR?= NFHOTpM4OiCq NX3iWYloTE2VTx?= MnLDTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iCwZYT3c5JsKG[xcn3heIlwdiCjdDCxMlghfG9iMUWgeW0> M1HodVIzQDV|OUmz
Plasmodium falciparum NIHnbpdHfW6ldHnvckBCe3OjeR?= MWKxNOKh|ryP MX6xOUBucW5? MlLmSG1UVw>? NEHiUFlKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? M1nZNlI1PTVyM{Ow
PC3 NWDwdpB[TnWwY4Tpc44hSXO|YYm= MV6wMlEh|ryP NHHaWno2KGh? NYLzOVZMTE2VTx?= NEexUZJKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M{fsV|E6PDZ{OUe1
DU145 M1z3bWZ2dmO2aX;uJGF{e2G7 M3TV[lAvOSEQvF2= MWq1JIg> MWPEUXNQ NFPUUVRKdmirYnn0d{BpfW2jbjDEWVE1PSClZXzsJIFlcGW|aX;uJIF1KDFyMDDuUS=> NUGxXII6OTl2NkK5O|U>
PC3 MnjOT4lv[XOnIFHzd4F6 NYS5TJNiOC5zIN88US=> MmWwOUBp NUW0VGN4TE2VTx?= M1PsbGlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= NVr2c3dCOTl2NkK5O|U>
DU145 MmrtT4lv[XOnIFHzd4F6 NYXvWI1POC5zIN88US=> Mn;GOUBp NWTtWlNnTE2VTx?= NFrCe2VKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> NXnmbGxmOTl2NkK5O|U>
PC3 M1PweGtqdmG|ZTDBd5NigQ>? MlzwNE4yKM7:TR?= MnPwOUBp MmnaSG1UVw>? MnvGTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O MVKxPVQ3Ojl5NR?=
DU145 MVrLbY5ie2ViQYPzZZk> MkL2NE4yKM7:TR?= MoDMOUBp M2XVTGROW09? NVm2RYZqUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= MXSxPVQ3Ojl5NR?=
Huh7 M2Dq[WFvfGm4aYLhcEBCe3OjeR?= M4jve|IvPSEQvF2= M4W3VFQh\GG7cx?= NIjN[5pFVVOR NYnsd3pUUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN NYnIfGp7OTd|NkC2O|Y>
C6/36 M4PVO2FvfGm4aYLhcEBCe3OjeR?= M17tNVIvPSEQvF2= M1TSUlQh\GG7cx?= MmTQSG1UVw>? NELpb5NKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MUKxO|M3ODZ5Nh?=
U937 M1nCbmZ2dmO2aX;uJGF{e2G7 MnjjNUDPxE1? MkHrNUBp MlTySG1UVw>? MVPS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? M1\qNFE4Pjh2MEm5
U937 NHPveJNHfW6ldHnvckBCe3OjeR?= MoDWNUDPxE1? M3TJRVEhcA>? M2\OT2ROW09? NGGx[|BT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MUGxO|Y5PDB7OR?=
murine mast cell NWT3Zm9kTnWwY4Tpc44hSXO|YYm= NXfXU5lmOSEQvF2= M{HFOFI1KGh? MlLPSG1UVw>? MknpTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? MYGxO|Y5PDB7OR?=
BV-173 NWfpbXh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMECwNFAxOTB7IN88US=> MUDTRW5ITVJ?
K-562 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6d49qUUN3ME2wMlAxODByMEK2OkDPxE1? NGLHfWdUSU6JRWK=
BL-70 NF:1R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjRSVJKSzVyPUCuNFAxODByOEKyJO69VQ>? NWC4VXVFW0GQR1XS
EM-2 MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1mzR2lEPTB;MD6wNFAxODFyODFOwG0> NXK2RnM5W0GQR1XS
LAMA-84 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnrWJhxUUN3ME2wMlAxODByM{KxJO69VQ>? NIDWNllUSU6JRWK=
MEG-01 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTBwMECwNFA6QCEQvF2= NYn6ZWZEW0GQR1XS
EoL-1-cell NYGzc5F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMECwNFE{OSEQvF2= M1HRV3NCVkeHUh?=
CTV-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HSd2lEPTB;MD6wNFAxPDB2IN88US=> M{jkNHNCVkeHUh?=
TE-15 M1Xlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj1TWM2OD1yLkCwOVg6KM7:TR?= MnLtV2FPT0WU
NOS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjmR3pKSzVyPUCuNFA3OTNizszN MmHIV2FPT0WU
D-336MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXkWlVKSzVyPUCuNFA3OyEQvF2= MYrTRW5ITVJ?
LB1047-RCC MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TXWGlEPTB;MD6wNFk5QSEQvF2= M1ToVnNCVkeHUh?=
LB996-RCC NVPnXpExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEC5PVEh|ryP NXXMS4R2W0GQR1XS
SW982 MmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\udW9pUUN3ME2wMlAyOTF3IN88US=> M2PPfXNCVkeHUh?=
TK10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;KTGlEPTB;MD6wNVE4PCEQvF2= MXrTRW5ITVJ?
A704 NGH6VWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjZSmtKSzVyPUCuNFE1QTFizszN MVrTRW5ITVJ?
TE-8 M{\qVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfiTWM2OD1yLkCxOVc3KM7:TR?= NXLUXm1GW0GQR1XS
DOHH-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnmRmdKSzVyPUCuNFE4OTlizszN MljjV2FPT0WU
HOP-62 NIC2N2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PqWWlEPTB;MD6wNVg{PCEQvF2= NVnYdWxsW0GQR1XS
TE-12 NGHOV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Ye3VXUUN3ME2wMlAyQDZzIN88US=> M4rJOnNCVkeHUh?=
KGN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S3UGlEPTB;MD6wNVk1OiEQvF2= MX3TRW5ITVJ?
NCI-H1648 Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqzXW1KSzVyPUCuNFIxOTFizszN NFq4WGlUSU6JRWK=
OS-RC-2 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vNW2lEPTB;MD6wNlA{KM7:TR?= MomzV2FPT0WU
GB-1 M1WxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhZZZoUUN3ME2wMlAzOTV5IN88US=> M1rTWnNCVkeHUh?=
RXF393 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nQN2lEPTB;MD6wNlM2PyEQvF2= NHPiTlZUSU6JRWK=
LC-2-ad NGLlN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXKTWM2OD1yLkCyOVg3KM7:TR?= M{G2WXNCVkeHUh?=
KS-1 NUnNU5l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3BVlk6UUN3ME2wMlAzPzNizszN NXXaV|hpW0GQR1XS
ETK-1 MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEK4N|Ih|ryP NXz4Xoc5W0GQR1XS
SW954 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7mdXpKSzVyPUCuNFI6OjdizszN M1:4SnNCVkeHUh?=
Becker NUD1NoxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\qSlZKSzVyPUCuNFMxODNizszN MUDTRW5ITVJ?
MZ1-PC Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDafXhKSzVyPUCuNFMyOTlizszN NVLxXGlKW0GQR1XS
ES6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMEOxPVMh|ryP NXWwSlQxW0GQR1XS
KURAMOCHI NHrwXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEO0PFch|ryP Mmm1V2FPT0WU
CGTH-W-1 NUT5UGVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEO1OFgh|ryP NGPKOWZUSU6JRWK=
VA-ES-BJ M1riRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G1PWlEPTB;MD6wN|kxOiEQvF2= NGjx[VJUSU6JRWK=
LXF-289 MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nQe2lEPTB;MD6wN|k2PiEQvF2= NFnOU5hUSU6JRWK=
MPP-89 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfCbI1KSzVyPUCuNFQxPDlizszN NF6wT5lUSU6JRWK=
SW872 M{nSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvs[HhlUUN3ME2wMlA1OTZzIN88US=> M3z0O3NCVkeHUh?=
SNB75 NXjlZWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof1TWM2OD1yLkC0OFM2KM7:TR?= MYrTRW5ITVJ?
PSN1 MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTLTWM2OD1yLkC0OFc1KM7:TR?= M3PIPXNCVkeHUh?=
LB831-BLC M3LvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrnTWM2OD1yLkC0OlA6KM7:TR?= NFz3U4JUSU6JRWK=
MFH-ino NYfWR2NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7sTWM2OD1yLkC0O|I1KM7:TR?= NV73RnU1W0GQR1XS
TGBC24TKB NInqc2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHmTWM2OD1yLkC0O|YyKM7:TR?= Ml3FV2FPT0WU
A388 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS4XVJKSzVyPUCuNFUxQTVizszN M4\DPHNCVkeHUh?=
BB30-HNC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HLNGlEPTB;MD6wOVQ{PyEQvF2= NFTqXXdUSU6JRWK=
GI-ME-N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTTWM2OD1yLkC2NVE5KM7:TR?= M37mZ3NCVkeHUh?=
TGBC1TKB MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPYTYhKSzVyPUCuNFYyPjRizszN MnXoV2FPT0WU
TE-10 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jETGlEPTB;MD6wOlM2PyEQvF2= M1\v[HNCVkeHUh?=
A498 NYftSG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLsZZplUUN3ME2wMlA4Ojh2IN88US=> NX3tU5ZxW0GQR1XS
TE-11 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n2S2lEPTB;MD6wO|g2QCEQvF2= NX\BPGdRW0GQR1XS
BB65-RCC NETqb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vUS2lEPTB;MD6wPFIzPyEQvF2= NXLzPFRzW0GQR1XS
C2BBe1 NYTEb|BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO2TWM2OD1yLkC4N|A5KM7:TR?= NX76cpNDW0GQR1XS
NCI-H747 NGTaO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW4TWM2OD1yLkC4N|YzKM7:TR?= M3jxOnNCVkeHUh?=
IST-MES1 NUjzWnVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqTWM2OD1yLkC4OVUzKM7:TR?= M1rYWHNCVkeHUh?=
KALS-1 NXradXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEm0PUDPxE1? MoTiV2FPT0WU
GCIY M3HQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILob|FKSzVyPUCuNFk3PTZizszN MmnHV2FPT0WU
RL95-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMUCzPEDPxE1? MkHUV2FPT0WU
TE-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mzW2lEPTB;MD6xNFU1KM7:TR?= MYDTRW5ITVJ?
NCI-H1355 MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O2U2lEPTB;MD6xNVAzQCEQvF2= MmXQV2FPT0WU
SW962 NGfsW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW1Oo1RUUN3ME2wMlEyOjl{IN88US=> MW\TRW5ITVJ?
KLE M4K3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XqO2lEPTB;MD6xNVMyPyEQvF2= M4T0UnNCVkeHUh?=
MC116 NEfzTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzUTWM2OD1yLkGxOFEh|ryP NFzielRUSU6JRWK=
NMC-G1 NEC5T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\xU3R2UUN3ME2wMlEyPjB4IN88US=> NIHlU5hUSU6JRWK=
KU812 NITz[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi3dldKSzVyPUCuNVE5QDNizszN M4jFSXNCVkeHUh?=
COLO-829 M3j3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMUKyNVMh|ryP MXLTRW5ITVJ?
NTERA-S-cl-D1 M1PLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfzVmZKSzVyPUCuNVIzQDNizszN MVjTRW5ITVJ?
IST-MEL1 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMUO0OUDPxE1? MkixV2FPT0WU
MLMA M1vx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ON4xSUUN3ME2wMlE1ODN{IN88US=> MnXHV2FPT0WU
LS-123 M2LkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rHV2lEPTB;MD6xOFA3PCEQvF2= M{m0VnNCVkeHUh?=
LB2518-MEL NEP5NmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMUSxOlIh|ryP MkPYV2FPT0WU
NB69 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml2wTWM2OD1yLkG0OFM3KM7:TR?= NHrReVhUSU6JRWK=
8-MG-BA M37NNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULGPVdjUUN3ME2wMlE2PDV6IN88US=> NFnzNm5USU6JRWK=
K5 M3XpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZRmlDUUN3ME2wMlE3PDh7IN88US=> MmPsV2FPT0WU
KINGS-1 NHj6cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7JZWV6UUN3ME2wMlE3PjZ4IN88US=> MkjyV2FPT0WU
SF268 M4XIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXYTWM2OD1yLkG3OFA1KM7:TR?= M4PnPXNCVkeHUh?=
PF-382 NUPDeZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPJR3ZwUUN3ME2wMlE4Pjd6IN88US=> NEDoSIdUSU6JRWK=
SH-4 NWX4SG56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDYTWM2OD1yLkG4OFE{KM7:TR?= MVfTRW5ITVJ?
NALM-6 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn22TWM2OD1yLkG5Nlk2KM7:TR?= M2LEfnNCVkeHUh?=
CP66-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInQc3ZKSzVyPUCuNVk2OzFizszN NXfkRnV[W0GQR1XS
697 NFfLSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rvPGlEPTB;MD6xPVk5PyEQvF2= M2HZenNCVkeHUh?=
CP67-MEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWxZmFKSzVyPUCuNlA1QDhizszN NES1UllUSU6JRWK=
DSH1 M1fwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfadGtmUUN3ME2wMlI1ODBzIN88US=> NHTGVWxUSU6JRWK=
HCE-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;RS3ZKSzVyPUCuNlY1OzlizszN MnL6V2FPT0WU
MZ2-MEL M2rsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTBwMki1N|ch|ryP M3j6TnNCVkeHUh?=
BL-41 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfUbGJPUUN3ME2wMlI6OTJ|IN88US=> MnHwV2FPT0WU
HUTU-80 NVj5PGg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwM{G0NkDPxE1? NFjNdJNUSU6JRWK=
LOXIMVI NVfkUYtRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnrTXhFUUN3ME2wMlMyPTB|IN88US=> NHrMVGZUSU6JRWK=
no-10 MmnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2wdFhjUUN3ME2wMlMyQTNzIN88US=> M3XYdnNCVkeHUh?=
KARPAS-422 NYrudYtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwM{O5PVch|ryP MUjTRW5ITVJ?
SW684 M17jXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwM{S5PEDPxE1? MnziV2FPT0WU
SF126 NHyxVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwM{W0NUDPxE1? MWrTRW5ITVJ?
D-263MG MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e2bGlEPTB;MD6zOlIzPCEQvF2= MYHTRW5ITVJ?
OVCAR-4 NWXYNIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:yTWM2OD1yLkO3OFM{KM7:TR?= NYjQbFc6W0GQR1XS
BB49-HNC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HydGlEPTB;MD6zPFU6QSEQvF2= M2Pp[3NCVkeHUh?=
ONS-76 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\2XWlEPTB;MD60Nlk2OSEQvF2= NHexZ|RUSU6JRWK=
MZ7-mel MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNEe5NVEh|ryP NXjxZXdJW0GQR1XS
RCC10RGB M2LCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLQc2FSUUN3ME2wMlQ6OTFizszN MUTTRW5ITVJ?
BOKU NXTubpd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7zTWM2OD1yLkS5NVM{KM7:TR?= M4TyZnNCVkeHUh?=
no-11 NYPKcYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHkTWM2OD1yLkWwNlI5KM7:TR?= MUTTRW5ITVJ?
IST-SL2 NYD3XFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwNUCzNFIh|ryP MlOwV2FPT0WU
RKO Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rwOmlEPTB;MD61Nlk3PiEQvF2= NYHaPHQ4W0GQR1XS
HT-144 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOzeFJQUUN3ME2wMlU{PjB7IN88US=> NIrNSXFUSU6JRWK=
NCI-H446 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTrTWM2OD1yLk[yO|Yh|ryP M33wV3NCVkeHUh?=
QIMR-WIL MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Dye2lEPTB;MD63NFYzQSEQvF2= NWjNXpRRW0GQR1XS
MHH-PREB-1 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jk[GlEPTB;MD63OFQ3QSEQvF2= M1;iU3NCVkeHUh?=
EW-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUixc|MyUUN3ME2wMlc3OTd6IN88US=> NFL6N5dUSU6JRWK=
EW-24 NFjKUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\HTWM2OD1yLke4NVY2KM7:TR?= MoTWV2FPT0WU
LB373-MEL-D NGXVdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHzUWxNUUN3ME2wMlgzPTB6IN88US=> NFnwSGNUSU6JRWK=
TE-9 NFzm[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXjNGp5UUN3ME2wMlg4PTN{IN88US=> NVPS[WNXW0GQR1XS
A3-KAW NEj0XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLZTWM2OD1yLkm4OFUzKM7:TR?= NIDMTXhUSU6JRWK=
A101D MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXETWM2OD1zLkCzNFQ{KM7:TR?= NFzwZ|hUSU6JRWK=
OCUB-M MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlTWM2OD1zLkC0OFEzKM7:TR?= NGL2coVUSU6JRWK=
ES4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHSxUpVKSzVyPUGuNFUyPDVizszN MmDvV2FPT0WU
TE-6 MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzKTWM2OD1zLkKxNlI3KM7:TR?= NV7BOoJFW0GQR1XS
D-502MG M{TpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZbolnUUN3ME2xMlI{Ozd4IN88US=> M{PHUXNCVkeHUh?=
KNS-42 NGq4RotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTFwMkS0NVIh|ryP NEK0R49USU6JRWK=
SNU-C2B NX3MZ2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTWeZFKSzVyPUGuN|A2QDlizszN NF7Zc4tUSU6JRWK=
NCI-H1838 NUf0[VZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PPTWlEPTB;MT6zNFc{OyEQvF2= NIjYRYxUSU6JRWK=
NKM-1 NH3UUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PJfGlEPTB;MT6zNFg2QSEQvF2= Ml7lV2FPT0WU
GI-1 NYT6SXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3eyOmlEPTB;MT6zOlIzKM7:TR?= NHPzVVFUSU6JRWK=
NB5 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTa[4FKSzVyPUGuN|k5OjdizszN NX23UJdWW0GQR1XS
CAS-1 NWPWNGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHHTWM2OD1zLkSwPVkzKM7:TR?= M4fxTHNCVkeHUh?=
HCE-T M1fxPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XNTmlEPTB;MT61OlcyPCEQvF2= M{XnTnNCVkeHUh?=
SBC-1 NGj2RWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHntZYlKSzVyPUGuOVc6QDRizszN M4TlWHNCVkeHUh?=
JiyoyeP-2003 NGnMZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwN{O0OlYh|ryP M{izXnNCVkeHUh?=
TE-5 NXT0S|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGzS4pKSzVyPUGuO|kyOzlizszN MU\TRW5ITVJ?
CAN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwOEKyOVIh|ryP NYTFZWdLW0GQR1XS
SK-UT-1 NWLPWWE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfaWYhKSzVyPUKuNVY3QTNizszN MlzHV2FPT0WU
JVM-2 M4X1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG2TWM2OD1{LkO2Nlg1KM7:TR?= NIft[FhUSU6JRWK=
LB771-HNC NELFbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rzOWlEPTB;Mj61O|U2OSEQvF2= NY\zWJlCW0GQR1XS
NCCIT NXK1b|R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHpTWM2OD1{Lki2OlE3KM7:TR?= M3XSXnNCVkeHUh?=
NCI-H2126 M2DMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFP3bZBKSzVyPUKuPFc2PTJizszN MYnTRW5ITVJ?
Calu-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTNwMEW3OFEh|ryP Mki4V2FPT0WU
SK-LMS-1 NVv2R4o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXeyWGtyUUN3ME2zMlEyQDh4IN88US=> MYrTRW5ITVJ?
ARH-77 NGfodYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrLTWM2OD1|LkS2PVE2KM7:TR?= MlzFV2FPT0WU
NB17 NW\0bZhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHubWs3UUN3ME2zMlY{QDR5IN88US=> NILBbZBUSU6JRWK=
A253 NHHQTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPETWM2OD1|LkezNlQ3KM7:TR?= NFvPO5NUSU6JRWK=
OPM-2 NFPzNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LpVGlEPTB;ND6yO|Y5PSEQvF2= MoW5V2FPT0WU
MV-4-11 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\ZTWM2OD12LkO2OFU1KM7:TR?= NFqxVmxUSU6JRWK=
SR NHHLOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXvbFVKSzVyPUSuOFk6PTRizszN M1;Sb3NCVkeHUh?=
KG-1 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O0cmlEPTB;ND62NFg1PSEQvF2= MUTTRW5ITVJ?
OCI-AML2 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXlOYFGUUN3ME21Mlg3OTV2IN88US=> Mof3V2FPT0WU
D-247MG NGrsUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHj[ZVKSzVyPU[uNVI2OTlizszN Mlv0V2FPT0WU
DJM-1 NVnEfWZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrzTWM2OD14LkS4OVU5KM7:TR?= MXnTRW5ITVJ?
RPMI-6666 NGP0SHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDHTWM2OD15LkK3NFY4KM7:TR?= NYLIb4dqW0GQR1XS
KARPAS-45 NVK0VZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfsNoQ2UUN3ME23MlUyPjdzIN88US=> MV7TRW5ITVJ?
LP-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HaeGlEPTB;Nz61OFc5OiEQvF2= NV;Yb4ZwW0GQR1XS
RS4-11 M2\jUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTdwNkW3PFch|ryP MVvTRW5ITVJ?
DU-4475 M3P5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LmS2lEPTB;OD6yNVY2OiEQvF2= M1vLRXNCVkeHUh?=
MONO-MAC-6 M4LVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRThwMkewOlYh|ryP MUfTRW5ITVJ?
NCI-SNU-16 M333NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELRNnFKSzVyPUiuOVYyOjhizszN NUTTeJdZW0GQR1XS
SJSA-1 M130[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRThwN{K4NFUh|ryP MULTRW5ITVJ?
MMAC-SF MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULIZ3FiUUN3ME24Mlc6OzB5IN88US=> NGm3b2lUSU6JRWK=
SK-NEP-1 NVTMW2lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom3TWM2OD16Lki5NVU2KM7:TR?= NELVd45USU6JRWK=
J-RT3-T3-5 M{LNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r6cmlEPTB;OD65OlUzQSEQvF2= NWD5VIpIW0GQR1XS
SKM-1 NYXJV4QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLtTWM2OD17LkCxO|M1KM7:TR?= Mnj3V2FPT0WU
LB2241-RCC NFXlXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX2WVJKSzVyPUmuNFIxOTJizszN NYr6NZl7W0GQR1XS
SIG-M5 NHqwS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XyVWlEPTB;OT6wNlQ6OyEQvF2= M3\1fXNCVkeHUh?=
EVSA-T NFviSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlwMke3PVMh|ryP NUHiO2xGW0GQR1XS
GT3TKB NGrPe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPmR5VKSzVyPUmuN|U2PDZizszN NFfFSJRUSU6JRWK=
NB6 NWjBfndiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzq[otKSzVyPUmuPVIzPTlizszN MWjTRW5ITVJ?
EHEB NVHEZ|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPrTXRKSzVyPUGwMlA3PTZizszN NITLNVlUSU6JRWK=
HEL NFu2fYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jp[WlEPTB;MUCuOFc4PiEQvF2= M3vqZXNCVkeHUh?=
ALL-PO NVr4Vll{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuzTWM2OD1zMD63PVM5KM7:TR?= M4q5WnNCVkeHUh?=
TGW MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLnSYdGUUN3ME2xNU4zQDJ6IN88US=> MVPTRW5ITVJ?
BC-3 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTaTWM2OD1zMj6xNVM5KM7:TR?= NETMT5VUSU6JRWK=
IA-LM NVzYUJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfWSmtwUUN3ME2xNk41PDR3IN88US=> NInaWJZUSU6JRWK=
UACC-257 M1XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPQdG9KSzVyPUGyMlkyQThizszN M2G5b3NCVkeHUh?=
KP-N-YS NY\Xc5dTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYj1fHJzUUN3ME2xNk46Ojh|IN88US=> NUfDbW44W0GQR1XS
Raji NVuxWIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF|Lke0PVch|ryP MojyV2FPT0WU
SF539 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF|Lki1OVch|ryP MlTJV2FPT0WU
DMS-153 NVPLe5lNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3zW3FKSzVyPUG0MlAxOjhizszN MY\TRW5ITVJ?
L-540 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;pTWM2OD1zNT6wOlczKM7:TR?= MYLTRW5ITVJ?
MN-60 NInaUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF3LkG5O|kh|ryP NYTUToRYW0GQR1XS
RPMI-8866 NY\UO|RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF5LkS0OVQh|ryP M1:3VnNCVkeHUh?=
NCI-H510A MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXmc4VYUUN3ME2xPU4{QTd|IN88US=> MVjTRW5ITVJ?
NB13 M{Lyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fJWGlEPTB;MUmuOFg4PyEQvF2= MU\TRW5ITVJ?
HAL-01 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn2RoI4UUN3ME2xPU44PTR|IN88US=> NGTjSIlUSU6JRWK=
NCI-H720 NXrOR4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OwT2lEPTB;MkCuNlc{OyEQvF2= M4PF[3NCVkeHUh?=
REH NF\xTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjUWVdKSzVyPUKwMlY{PTdizszN NVSzOo5OW0GQR1XS
KNS-81-FD NVyzZ2VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnIfm5KSzVyPUKzMlE1PiEQvF2= M1nE[nNCVkeHUh?=
HC-1 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rod2lEPTB;MkSuOVU2OSEQvF2= MVvTRW5ITVJ?
NCI-H2141 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJ2Lke3OVQh|ryP NVy2eGJVW0GQR1XS
MOLT-4 Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTJ4Lk[3OVMh|ryP MYnTRW5ITVJ?
OMC-1 NGLOfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTJ5LkG0NlIh|ryP MWfTRW5ITVJ?
LC-1F NYDtZ2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XncmlEPTB;MkeuN|I1PSEQvF2= NGD5[ZZUSU6JRWK=
NCI-H1304 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ6LkG2Nlgh|ryP MoXBV2FPT0WU
BC-1 NF3hXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLWTWM2OD1{OD62OVEh|ryP Mn;aV2FPT0WU
NCI-H64 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ7Lk[yOVMh|ryP NFW1NVZUSU6JRWK=
MOLT-16 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTJ7Lk[yPVIh|ryP MXPTRW5ITVJ?
U-87-MG MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV30TFV3UUN3ME2zNE44PjZizszN MnTqV2FPT0WU
GAK NIPUfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr3doY3UUN3ME2zNU4zPjh4IN88US=> NWm3Wm5UW0GQR1XS
ES8 NU\I[W1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjoTWM2OD1|Mj6xNlUzKM7:TR?= M4\RNHNCVkeHUh?=
HCC1599 M2XGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7kOG5KSzVyPUOyMlM{OjVizszN NWXCd5dYW0GQR1XS
EB-3 NF7MZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:0[FBKSzVyPUO0MlMyOTdizszN MlmzV2FPT0WU
HCC1187 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlGxTWM2OD1|NT64NFUzKM7:TR?= NGm5V|BUSU6JRWK=
SK-PN-DW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITX[HhKSzVyPUO2MlE6PDNizszN NULZUZZ5W0GQR1XS
JVM-3 M1zwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzVUoVKSzVyPUO3MlI{OzhizszN MX7TRW5ITVJ?
HCC2157 M{HPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K3NGlEPTB;M{euPVk1PiEQvF2= MlfwV2FPT0WU
A4-Fuk NIrjSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzGb5RKSzVyPUO4MlExODlizszN NYHh[G5FW0GQR1XS
COR-L279 M2i4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTRyLkK4OVEh|ryP MYTTRW5ITVJ?
DEL NIDI[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTRzLkmwPFYh|ryP Mo\nV2FPT0WU
NCI-H1395 M1HGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLDTWM2OD12Mj6wNVY{KM7:TR?= NHHqdHdUSU6JRWK=
MHH-NB-11 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDFV5h[UUN3ME20N{4xQDF6IN88US=> NICwOmJUSU6JRWK=
NCI-H2107 NY[ycXBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M324Z2lEPTB;NEOuOFg1PiEQvF2= Ml3QV2FPT0WU
NEC8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HMdGlEPTB;NESuN|M3KM7:TR?= MoDsV2FPT0WU
COLO-684 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTRO3NKSzVyPUS2MlIzPThizszN NXXUfmpOW0GQR1XS
LS-411N MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\6W2lEPTB;NEiuOFc1QCEQvF2= NVflV2FoW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 2年-20℃
6月-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

文献中の引用 (62)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ